Skip to main content
Top
Published in: Annals of Hematology 10/2013

01-10-2013 | Original Article

Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin’s lymphoma

Authors: Ahmed M. L. Bedewy, Maha M. Adel Elgammal, Magdy M. L. Bedewy, Shereen M. EL-Maghraby

Published in: Annals of Hematology | Issue 10/2013

Login to get access

Abstract

The soluble decoy receptor 3 (DcR3) is a member of the tumor necrosis factor receptor superfamily whose overexpression has been observed in several human malignancies. Survivin is one of the inhibitors of apoptosis proteins that are thought to play an important role in the pathogenesis of malignancies. We aimed to evaluate the expression of DcR3 in relation to survivin in B cell non-Hodgkin`s lymphoma (NHL) and then we focused on patients with diffuse large B cell non-Hodgkin’s lymphoma (DLBCL) (50 cases) and correlated DcR3 expression with survivin expression and other prognostic parameters. Fifteen subjects with reactive lymphoid hyperplasia were included as controls. The expression of DcR3 and survivin were analyzed by immunohistochemistry on formalin-fixed paraffin-embedded lymph node sections from 80 cases of B cell NHL and 15 controls. Bone marrow biopsy sections of patients were also immunostained with the previous markers. Results: DcR3 expression was found in 32.5 % of B cell NHL patients versus 6.7 % of controls (p <0.001) and was associated with the aggressive/highly aggressive subtypes. DcR3 was strongly expressed in 30 % of DLBCL patients, where it was associated with survivin expression, high international prognostic index (IPI), the presence of extra nodal disease, ECOG performance status >1, reduced remission rates and shorter event-free survival. The expression of survivin was 40 % in B cell NHL patients versus 13.3 % in the control group (p <0.001). The expression of survivin in aggressive/highly aggressive B cell NHL was significantly higher than that in indolent B cell NHL. Survivin expression has been detected in 44 % of the DLBCL patients and was associated with their clinical stage and shorter event-free survival (p = 0.026). Bone marrow biopsy sections from DLBCL patients showed significant DcR3 and survivin over expressions in sections with infiltration by lymphoma cells than sections with no infiltration. Conclusion: DcR3 expression was associated with other prognostic factors including survivin, reduced remission rates, and shorter event-free survival. Survivin is closely related to aggressive/highly aggressive subtypes of B cell NHL and is associated with shorter event-free survival. Both DcR3 and survivin expressions on bone marrow sections can be of help in diagnosing bone marrow infiltration.
Literature
1.
go back to reference Jacquemin G, Granci V, Gallouet AS, Lalaoui N, Morlé A, Iessi E, Morizot A, Garrido C, Guillaudeux T, Micheau O (2012) Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin’s lymphoma B cells. Haematologica 97(1):38–46. doi:10.3324/haematol.2011.046466, Epub 2011 Sep 20PubMedCrossRef Jacquemin G, Granci V, Gallouet AS, Lalaoui N, Morlé A, Iessi E, Morizot A, Garrido C, Guillaudeux T, Micheau O (2012) Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin’s lymphoma B cells. Haematologica 97(1):38–46. doi:10.​3324/​haematol.​2011.​046466, Epub 2011 Sep 20PubMedCrossRef
2.
go back to reference Tilly H, Dreyling M (2010) Diffuse large B cell non-Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(5):172–174CrossRef Tilly H, Dreyling M (2010) Diffuse large B cell non-Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(5):172–174CrossRef
3.
go back to reference Kumar V, Abbas AK, Fausto N, Aster JC (2009) Robbins and Cotran pathologic basis of disease. Elsevier Health Sciences Kumar V, Abbas AK, Fausto N, Aster JC (2009) Robbins and Cotran pathologic basis of disease. Elsevier Health Sciences
4.
go back to reference Fisher RI, Gaynor ER, Dahlberg S et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328(14):1002–1006PubMedCrossRef Fisher RI, Gaynor ER, Dahlberg S et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328(14):1002–1006PubMedCrossRef
5.
go back to reference Groves FD, Linet MA, Travis LB, Devesa SS (2000) Cancer surveillance series: non-Hodgkin’s lymphoma: incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 19:1240–1251CrossRef Groves FD, Linet MA, Travis LB, Devesa SS (2000) Cancer surveillance series: non-Hodgkin’s lymphoma: incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 19:1240–1251CrossRef
6.
go back to reference Bartl R, Frisch B, Burkhardt R et al (1984) Lymphoproliferations in the bone marrow: identification and evolution; classification and staging. J Clin Pathol 37:233–254PubMedCrossRef Bartl R, Frisch B, Burkhardt R et al (1984) Lymphoproliferations in the bone marrow: identification and evolution; classification and staging. J Clin Pathol 37:233–254PubMedCrossRef
7.
go back to reference Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S (2006) The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol 76(6):473–480PubMedCrossRef Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S (2006) The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol 76(6):473–480PubMedCrossRef
8.
go back to reference Pitti RM, Marsters SA, Lawrence DA et al (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699–703PubMedCrossRef Pitti RM, Marsters SA, Lawrence DA et al (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699–703PubMedCrossRef
9.
go back to reference Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, Cho YH, Ullrich S, Kanakaraj P, Carrell J, Boyd E, Olsen HS, Hu G, Pukac L, Liu D, Ni J, Kim S, Gentz R, Feng P, Moore PA, Ruben SM, Wei P (2002) TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell co-stimulator. Immunity 16:479–492PubMedCrossRef Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, Cho YH, Ullrich S, Kanakaraj P, Carrell J, Boyd E, Olsen HS, Hu G, Pukac L, Liu D, Ni J, Kim S, Gentz R, Feng P, Moore PA, Ruben SM, Wei P (2002) TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell co-stimulator. Immunity 16:479–492PubMedCrossRef
10.
go back to reference Ge Z, Sanders AJ, Ye L, Jiang WG (2011) Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer. Exp Ther Med 2(2):167–172PubMed Ge Z, Sanders AJ, Ye L, Jiang WG (2011) Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer. Exp Ther Med 2(2):167–172PubMed
11.
go back to reference Hsu TL, Wu YY, Chang YC, Yang CY, Lai MZ, Su WB, Hsieh SL (2005) Attenuation of Th1 response in decoy receptor 3 transgenic mice. J Immunol 175:5135–5145PubMed Hsu TL, Wu YY, Chang YC, Yang CY, Lai MZ, Su WB, Hsieh SL (2005) Attenuation of Th1 response in decoy receptor 3 transgenic mice. J Immunol 175:5135–5145PubMed
12.
go back to reference Macher-Goeppinger S, Aulmann S, Wagener N, Funke B, Tagscherer KE, Haferkamp A, Hohenfellner M, Kim S, Autschbach F, Schirmacher P, Roth W (2008) Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia 10:1049–1056PubMed Macher-Goeppinger S, Aulmann S, Wagener N, Funke B, Tagscherer KE, Haferkamp A, Hohenfellner M, Kim S, Autschbach F, Schirmacher P, Roth W (2008) Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia 10:1049–1056PubMed
13.
go back to reference Takahama Y, Yamada Y, Emoto K et al (2002) The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 5:61–68PubMedCrossRef Takahama Y, Yamada Y, Emoto K et al (2002) The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 5:61–68PubMedCrossRef
14.
go back to reference Guha M, Altieri DC (2009) Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 8:2708–2710PubMedCrossRef Guha M, Altieri DC (2009) Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 8:2708–2710PubMedCrossRef
15.
go back to reference Li F, Yang J, Ramnath N et al (2005) Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 114:509–512PubMedCrossRef Li F, Yang J, Ramnath N et al (2005) Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 114:509–512PubMedCrossRef
16.
go back to reference Harfouche R, Hassessian HM, Guo Y et al (2002) Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc Res 64:135–147PubMedCrossRef Harfouche R, Hassessian HM, Guo Y et al (2002) Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc Res 64:135–147PubMedCrossRef
17.
go back to reference Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ (2004) Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 22:1682–1688PubMedCrossRef Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ (2004) Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 22:1682–1688PubMedCrossRef
18.
go back to reference Dohi T, Okada K, Xia F et al (2004) An IAP-IAP complex inhibits apoptosis. J Biol Chem 279:34087–34090PubMedCrossRef Dohi T, Okada K, Xia F et al (2004) An IAP-IAP complex inhibits apoptosis. J Biol Chem 279:34087–34090PubMedCrossRef
19.
go back to reference Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 8:917–921CrossRef Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 8:917–921CrossRef
20.
go back to reference Siegel S, Wagner A, Schmitz N, Zeis M (2003) Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol 122:911–914PubMedCrossRef Siegel S, Wagner A, Schmitz N, Zeis M (2003) Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol 122:911–914PubMedCrossRef
21.
go back to reference Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRef Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRef
22.
go back to reference Lister TA, Crowther D, Sutcliffe SB et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Costwolds meeting. J Clin Oncol 7(11):1630–1636PubMed Lister TA, Crowther D, Sutcliffe SB et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Costwolds meeting. J Clin Oncol 7(11):1630–1636PubMed
23.
go back to reference The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329(14):987–994CrossRef The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329(14):987–994CrossRef
24.
go back to reference Kate C, Anthony HG (2010) Non-Hodgkin lymphoma. Postgraduate Hematology,sixth edition, by Blackwell Publishing 655–685 Kate C, Anthony HG (2010) Non-Hodgkin lymphoma. Postgraduate Hematology,sixth edition, by Blackwell Publishing 655–685
25.
go back to reference Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working group. J Clin Oncol 17:1244–1253PubMed Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working group. J Clin Oncol 17:1244–1253PubMed
26.
go back to reference Chang PM, Chen PM, Hsieh SL, Tzeng CH, Liu JH, Chiou TJ, Wang WS, Yen CC, Gau JP, Yang MH (2008) Expression of a soluble decoy receptor 3 in patients with diffuse large B cell lymphoma predicts clinical outcome. Int J Oncol 33(3):549–554PubMed Chang PM, Chen PM, Hsieh SL, Tzeng CH, Liu JH, Chiou TJ, Wang WS, Yen CC, Gau JP, Yang MH (2008) Expression of a soluble decoy receptor 3 in patients with diffuse large B cell lymphoma predicts clinical outcome. Int J Oncol 33(3):549–554PubMed
27.
go back to reference Aktaş S, Kargi A, Olgun N, Diniz G, Erbay A, Vergin C (2009) Prognostic significance of cell proliferation and apoptosis-regulating proteins in Epstein–Barr virus positive and negative pediatric non-Hodgkin’s lymphoma. Pathol Oncol Res 15(3):345–350PubMedCrossRef Aktaş S, Kargi A, Olgun N, Diniz G, Erbay A, Vergin C (2009) Prognostic significance of cell proliferation and apoptosis-regulating proteins in Epstein–Barr virus positive and negative pediatric non-Hodgkin’s lymphoma. Pathol Oncol Res 15(3):345–350PubMedCrossRef
28.
go back to reference Watanuki-Miyauchi R, Kojima Y, Tsurumi H, Hara T, Goto N, Kasahara S, Saio M, Moriwaki H, Takami T (2005) Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B cell lymphoma and its subtypes. Pathol Int 55(6):324–330PubMedCrossRef Watanuki-Miyauchi R, Kojima Y, Tsurumi H, Hara T, Goto N, Kasahara S, Saio M, Moriwaki H, Takami T (2005) Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B cell lymphoma and its subtypes. Pathol Int 55(6):324–330PubMedCrossRef
29.
go back to reference Arber DA, George TI (2005) Bone marrow biopsy involvement by non-Hodgkin’s lymphoma: frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens. Am J Surg Pathol 29(12):1549–1557PubMedCrossRef Arber DA, George TI (2005) Bone marrow biopsy involvement by non-Hodgkin’s lymphoma: frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens. Am J Surg Pathol 29(12):1549–1557PubMedCrossRef
30.
go back to reference Liang Q, Wang B, Li G (2009) DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters. J Zhejiang Univ Sci B 10(9):675–682PubMedCrossRef Liang Q, Wang B, Li G (2009) DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters. J Zhejiang Univ Sci B 10(9):675–682PubMedCrossRef
31.
go back to reference Paydas S, Ergin M, Erdogan S, Seydaoglu G, Yavuz S, Disel U (2008) Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas. Leuk Res 32(2):243–50 Paydas S, Ergin M, Erdogan S, Seydaoglu G, Yavuz S, Disel U (2008) Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas. Leuk Res 32(2):243–50
32.
go back to reference Zuo XL, Zhou X, Meng J, Zhang KJ, Liu XH, Yang HQ (2006) A study on the expression of myeloid cell leukemia 1 proteins and survivin and their relation with B cell apoptosis in non-Hodgkin’s lymphoma. Zhonghua Nei Ke Za Zhi 45(2):133–135PubMed Zuo XL, Zhou X, Meng J, Zhang KJ, Liu XH, Yang HQ (2006) A study on the expression of myeloid cell leukemia 1 proteins and survivin and their relation with B cell apoptosis in non-Hodgkin’s lymphoma. Zhonghua Nei Ke Za Zhi 45(2):133–135PubMed
33.
go back to reference Gu X, Lin HL (2004) Analysis of survivin expression in subtypes of lymphoma. Ai Zheng 23(6):655–661PubMed Gu X, Lin HL (2004) Analysis of survivin expression in subtypes of lymphoma. Ai Zheng 23(6):655–661PubMed
34.
go back to reference Lin L, Min Z, Ping Z (2007) Expression of PLK1 and survivin in diffuse large B cell lymphoma. Leuk Lymphoma 48:2179–2183CrossRef Lin L, Min Z, Ping Z (2007) Expression of PLK1 and survivin in diffuse large B cell lymphoma. Leuk Lymphoma 48:2179–2183CrossRef
35.
go back to reference Li J, Wu H (2006) Expression of survivin in human non-Hodgkin lymphoma and its correlation with proliferation and angiogenesis. J Huazhong Univ Sci Technolog Med Sci 26(5):504–507PubMedCrossRef Li J, Wu H (2006) Expression of survivin in human non-Hodgkin lymphoma and its correlation with proliferation and angiogenesis. J Huazhong Univ Sci Technolog Med Sci 26(5):504–507PubMedCrossRef
36.
go back to reference Markovic O, Marisavljevic D, Cemerikic-Martinovic V, Martinovic T, Filipovic B, Stanisavljevic D, Zivković R, Hajder J, Stanisavljevic N, Mihaljevic B (2012) Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL). Med Oncol 29(5):3515–3521PubMedCrossRef Markovic O, Marisavljevic D, Cemerikic-Martinovic V, Martinovic T, Filipovic B, Stanisavljevic D, Zivković R, Hajder J, Stanisavljevic N, Mihaljevic B (2012) Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL). Med Oncol 29(5):3515–3521PubMedCrossRef
37.
go back to reference Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H et al (2000) Prognostic significance of survivin expression in diffuse large B cell lymphomas. Blood 96(5):1921–1925PubMed Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H et al (2000) Prognostic significance of survivin expression in diffuse large B cell lymphomas. Blood 96(5):1921–1925PubMed
38.
go back to reference Sung J, Lim S, Kim Y, Lee J (2010) Prognostic significance of pSTAT3 and survivin expression in diffuse large B cell lymphoma. Basic and Appl Pathol 3(1):7–13CrossRef Sung J, Lim S, Kim Y, Lee J (2010) Prognostic significance of pSTAT3 and survivin expression in diffuse large B cell lymphoma. Basic and Appl Pathol 3(1):7–13CrossRef
39.
go back to reference Paydas S, Seydaoglu G, Ergin M et al (2009) Prognostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Leuk Res 33:1627–1635PubMedCrossRef Paydas S, Seydaoglu G, Ergin M et al (2009) Prognostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Leuk Res 33:1627–1635PubMedCrossRef
40.
go back to reference Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–584PubMedCrossRef Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–584PubMedCrossRef
41.
go back to reference Mainou-Fowler T, Overman LM, Dignum H et al (2008) A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B cell lymphoma and improves the prognostic value of bcl-2. Int J Oncol 32:59–68PubMed Mainou-Fowler T, Overman LM, Dignum H et al (2008) A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B cell lymphoma and improves the prognostic value of bcl-2. Int J Oncol 32:59–68PubMed
42.
go back to reference Kuttler F, Valnet-Rabier MB, Angonin R, Ferrand C, Deconinck E, Mougin C, Cahn JY, Fest T (2002) Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia 16(4):726–735PubMedCrossRef Kuttler F, Valnet-Rabier MB, Angonin R, Ferrand C, Deconinck E, Mougin C, Cahn JY, Fest T (2002) Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia 16(4):726–735PubMedCrossRef
43.
go back to reference Gandhi AM, Ben-Ezra JM (2004) Do Bcl-2 and survivin help distinguish benign from malignant B cell lymphoid aggregates in bone marrow biopsies? J Clin Lab Anal 18(6):285–288PubMedCrossRef Gandhi AM, Ben-Ezra JM (2004) Do Bcl-2 and survivin help distinguish benign from malignant B cell lymphoid aggregates in bone marrow biopsies? J Clin Lab Anal 18(6):285–288PubMedCrossRef
44.
go back to reference Ohshima K, Haraoka S, Sugihara M, Suzumiya J, Kawasaki C, Kanda M, Kikuchi M (2000) Amplification and expression of a decoy receptor for Fas ligand (DcR3) in virus (EBV or HTLV-1) associated lymphomas. Cancer Lett 160:89–97PubMedCrossRef Ohshima K, Haraoka S, Sugihara M, Suzumiya J, Kawasaki C, Kanda M, Kikuchi M (2000) Amplification and expression of a decoy receptor for Fas ligand (DcR3) in virus (EBV or HTLV-1) associated lymphomas. Cancer Lett 160:89–97PubMedCrossRef
45.
go back to reference Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, Soderman A, Galloway SM, Liu Q, Austin CP, Caskey CT (2000) Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci USA 97(3):1230–1235PubMedCrossRef Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, Soderman A, Galloway SM, Liu Q, Austin CP, Caskey CT (2000) Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci USA 97(3):1230–1235PubMedCrossRef
Metadata
Title
Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin’s lymphoma
Authors
Ahmed M. L. Bedewy
Maha M. Adel Elgammal
Magdy M. L. Bedewy
Shereen M. EL-Maghraby
Publication date
01-10-2013
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 10/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1775-4

Other articles of this Issue 10/2013

Annals of Hematology 10/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.